To enhance the efficiency of the CAR-NK92-TRAIL cells against MM, we explored combination therapy with molecules capable of augmenting the effects of both the anti-BCMA CAR and secreted TRAIL. This evidence concerns the gene TNFSF10 and Miyoshi myopathy.